Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Emerging Techniques Put A New Twist On Ankle Repair
People with ankle injuries who do not respond successfully to initial treatment may have a second chance at recovery, thanks to two new procedures developed to restore the injured area, according to a study published in the July 2009 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS).

Endocrine Society Announces 2009 Laureate Award Winners
The Endocrine Society is pleased to announce the 2009 Laureate Awards established in 1944 to recognize the highest achievements in endocrinology including: science, leadership, teaching and service. This year"s Laureate Awards were presented at ENDO 09, the 91st Annual Meeting of The Endocrine Society, being held June 10-13, in Washington, DC.
News of the day
Medical Students Climb Everest To Study Immunity
Mountain climbers and adventurers who aspire to ascent Mount Everest have more information on immune function and the onset of acute mountain sickness (AMS), thanks to research presented today at the 56th Annual Meeting of the American College of Sports Medicine in Seattle. A team of medical students climbed to Everest Base Camp in order to find physical factors that would reveal information about illness severity in association with immune and hormonal responses to high-altitude exposure.
Sexual Health

Seattle Genetics To Present SGN-35 And Lintuzumab Clinical Data At The European Hematology Association Congress

Seattle Genetics, Inc. (Nasdaq:SGEN) announced that data from a phase I clinical trial evaluating every three week dosing of SGN-35 and a phase I clinical trial of lintuzumab (SGN-33) will be reported at the 14th Congress of the European Hematology Association (EHA) being held June 4-7, 2009 in Berlin, Germany. The abstracts are available from the EHA website at http://www.ehaweb.org. "In our SGN-35 presentation at EHA, we will provide additional data on durability of response and progression-free survival of patients in our every three week dosing study," said Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics. "In addition, we will report a strong concordance between investigator-assessed and independent review of responses in the trial." The SGN-35 abstract is titled "Robust antitumor activity of the antibody-drug conjugate SGN-35 when administered every three weeks to patients with relapsed or refractory CD30-positive hematologic malignancies in a phase I study," (Abstract #503). Updated data will be presented in an oral presentation on June 6, 2009, during a clinical session on Hodgkin lymphoma. Seattle Genetics is advancing SGN-35 in an ongoing pivotal trial for relapsed and refractory Hodgkin lymphoma and a planned phase II trial for systemic anaplastic large cell lymphoma. The pivotal trial is being conducted under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). SGN-35 is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody attached by an enzyme cleavable linker to a potent, synthetic drug payload, monomethyl auristatin E (MMAE), using Seattle Genetics" proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into CD30-expressing tumor cells, resulting in targeted cell-killing. The lintuzumab abstract, #833, is titled "Prolonged exposure to lintuzumab monotherapy in acute myeloid leukemia and myelodysplastic syndromes - results of a phase I trial." The data will be presented in an acute myeloid leukemia (AML) poster session on June 6, 2009. "The presentation on lintuzumab will provide complete data from our phase I single-agent clinical trial in more than 80 patients," added Dr. Reynolds. "Findings will include data on the tolerability profile and objective responses with lintuzumab as monotherapy in AML and myelodysplastic syndromes, primarily in older patients who were not candidates for intensive therapies." Lintuzumab is a humanized monoclonal antibody targeting CD33. Seattle Genetics is conducting a phase IIb randomized, double-blind, placebo-controlled clinical trial evaluating whether the combination of lintuzumab and low-dose cytarabine chemotherapy extends overall survival compared to low-dose cytarabine plus placebo in previously untreated AML patients age 60 and older who decline intensive chemotherapy. Full accrual of 210 patients to the phase IIb trial is complete, and data are expected in the first half of 2010. Seattle Genetics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009